KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Common Equity (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Common Equity for 17 consecutive years, with $18.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 13.29% to $18.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $18.5 billion, a 13.29% increase, with the full-year FY2025 number at $18.5 billion, up 13.29% from a year prior.
  • Common Equity was $18.5 billion for Q4 2025 at Bristol Myers Squibb, roughly flat from $18.6 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $44.4 billion in Q4 2021 to a low of -$43.7 billion in Q2 2024.
  • A 5-year average of -$3.4 billion and a median of $177.5 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 73835.0% in 2021, then plummeted 76749.12% in 2024.
  • Bristol Myers Squibb's Common Equity stood at $44.4 billion in 2021, then crashed by 99.87% to $57.0 million in 2022, then soared by 412.28% to $292.0 million in 2023, then surged by 5494.18% to $16.3 billion in 2024, then grew by 13.29% to $18.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Common Equity are $18.5 billion (Q4 2025), $18.6 billion (Q3 2025), and $54.0 million (Q2 2025).